Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Brain Res Bull ; 134: 24-29, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28655601

ABSTRACT

BACKGROUND AND PURPOSE: Intracerebral hemorrhage (ICH) is a particularly devastating form of stroke with high mortality and morbidity. Hematomas are the primary cause of neurologic deficits associated with ICH. The products of hematoma are recognized as neurotoxins and the main contributors to edema formation and tissue damage after ICH. Finding a means to efficiently promote absorption of hematoma is a novel clinical challenge for ICH. Peroxisome proliferator-activated receptor gamma (PPARγ) and nuclear factor erythroid 2-related factor 2 (Nrf2), had been shown that, can take potential roles in the endogenous hematoma clearance. However, monascin, a novel natural Nrf2 activator with PPARγ agonist, has not been reported to play a role in ICH. This study was designed to evaluate the effect of monascin on neurological deficits, hematoma clearance and edema extinction in a model of ICH in rats. METHODS: 164 adult male Sprague-Dawley (SD) rats were randomly divided into sham; vehicle; monascin groups with low dosages (1mg/kg/day), middle dosages (5mg/kg/day) and high dosages (10mg/kg/day) respectively. Animals were euthanized at 1, 3 and 7days following neurological evaluation after surgery. We examined the effect of monascin on the brain water contents, blood brain barrier (BBB) permeability and hemoglobin levels, meanwhile reassessed the volume of hematoma and edema around the hematoma by Magnetic Resonance Imaging (MRI) in each group. RESULTS: The high dosage of monascin significantly improved neurological deficits, reduced the volume of hematoma in 1-7days after ICH, decreased BBB permeability and edema formation in 1-3days following ICH. CONCLUSION: Our study demonstrated that the high dosage of monascin played a neuroprotective role in ICH through reducing BBB permeability, edema and hematoma volume.


Subject(s)
Blood-Brain Barrier/drug effects , Brain Edema/drug therapy , Cerebral Hemorrhage/drug therapy , Hematoma/drug therapy , Heterocyclic Compounds, 3-Ring/pharmacology , Neuroprotective Agents/pharmacology , Animals , Blood-Brain Barrier/metabolism , Blood-Brain Barrier/pathology , Brain Edema/diagnostic imaging , Brain Edema/metabolism , Brain Edema/pathology , Capillary Permeability/drug effects , Capillary Permeability/physiology , Cerebral Hemorrhage/diagnostic imaging , Cerebral Hemorrhage/metabolism , Cerebral Hemorrhage/pathology , Disease Models, Animal , Dose-Response Relationship, Drug , Hematoma/diagnostic imaging , Hematoma/metabolism , Hematoma/pathology , Male , NF-E2-Related Factor 2/metabolism , PPAR gamma/metabolism , Random Allocation , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...